Destination Wealth Management Purchases New Stake in Fresenius Medical Care AG & Co. (FMS)

Destination Wealth Management purchased a new stake in Fresenius Medical Care AG & Co. (NYSE:FMS) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 3,146 shares of the company’s stock, valued at approximately $158,000.

Several other large investors have also modified their holdings of the company. Acadian Asset Management LLC acquired a new stake in Fresenius Medical Care AG & Co. during the second quarter worth about $106,000. Atwood & Palmer Inc. grew its position in Fresenius Medical Care AG & Co. by 111.1% during the first quarter. Atwood & Palmer Inc. now owns 2,204 shares of the company’s stock worth $113,000 after buying an additional 1,160 shares in the last quarter. Signaturefd LLC acquired a new stake in Fresenius Medical Care AG & Co. during the first quarter worth about $121,000. Checchi Capital Advisers LLC acquired a new stake in Fresenius Medical Care AG & Co. during the first quarter worth about $202,000. Finally, Intercontinental Wealth Advisors LLC acquired a new stake in Fresenius Medical Care AG & Co. during the second quarter worth about $203,000. 2.49% of the stock is currently owned by institutional investors.

Get Fresenius Medical Care AG & Co. alerts:

Fresenius Medical Care AG & Co. opened at $49.49 on Thursday, according to Marketbeat Ratings. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.01 and a current ratio of 1.26. The company has a market cap of $29.80 billion, a price-to-earnings ratio of 22.39, a P/E/G ratio of 2.78 and a beta of 0.74. Fresenius Medical Care AG & Co. has a 1-year low of $44.88 and a 1-year high of $57.94.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its quarterly earnings data on Tuesday, July 31st. The company reported $0.54 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.06). The company had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.28 billion. Fresenius Medical Care AG & Co. had a net margin of 11.65% and a return on equity of 11.11%. The firm’s revenue for the quarter was down 5.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.89 earnings per share. sell-side analysts predict that Fresenius Medical Care AG & Co. will post 2.58 EPS for the current year.

A number of research firms recently weighed in on FMS. Bank of America began coverage on Fresenius Medical Care AG & Co. in a research report on Monday, July 9th. They set a “buy” rating on the stock. Zacks Investment Research raised Fresenius Medical Care AG & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 3rd. Royal Bank of Canada reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a report on Tuesday. Credit Suisse Group downgraded Fresenius Medical Care AG & Co. from an “outperform” rating to a “neutral” rating in a report on Thursday, July 5th. Finally, DZ Bank reaffirmed a “buy” rating on shares of Fresenius Medical Care AG & Co. in a report on Thursday, April 5th. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $54.67.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.

Further Reading: Book Value Per Share �� BVPS

Icon (ICLR) Downgraded by Zacks Investment Research to “Hold”

Icon (NASDAQ:ICLR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “

Get Icon alerts:

A number of other equities research analysts have also issued reports on the stock. BidaskClub raised shares of Icon from a “sell” rating to a “hold” rating in a report on Thursday, April 12th. Jefferies Financial Group increased their price objective on shares of Icon to $150.00 and gave the company a “buy” rating in a report on Friday, June 1st. SunTrust Banks increased their price objective on shares of Icon to $153.00 and gave the company a “buy” rating in a report on Thursday, July 26th. Robert W. Baird reaffirmed a “buy” rating and set a $154.00 price objective on shares of Icon in a report on Thursday, July 26th. Finally, KeyCorp increased their price objective on shares of Icon from $130.00 to $152.00 and gave the company an “overweight” rating in a report on Monday, June 18th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $138.80.

Shares of ICLR opened at $139.00 on Thursday. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.29. Icon has a 1 year low of $101.00 and a 1 year high of $146.31. The company has a market cap of $7.45 billion, a price-to-earnings ratio of 25.79, a P/E/G ratio of 1.96 and a beta of 0.45.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, July 25th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.48 by ($0.17). Icon had a net margin of 13.69% and a return on equity of 26.71%. The company had revenue of $641.60 million for the quarter, compared to analysts’ expectations of $618.64 million. During the same period last year, the business earned $1.34 earnings per share. The company’s quarterly revenue was up 48.9% compared to the same quarter last year. analysts forecast that Icon will post 6.08 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of ICLR. BlackRock Inc. boosted its position in shares of Icon by 8.2% during the 4th quarter. BlackRock Inc. now owns 39,201 shares of the medical research company’s stock valued at $4,397,000 after acquiring an additional 2,961 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Icon by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 33,612 shares of the medical research company’s stock valued at $3,769,000 after acquiring an additional 1,073 shares during the last quarter. Gotham Asset Management LLC bought a new position in shares of Icon during the 4th quarter valued at approximately $209,000. Dean Capital Investments Management LLC boosted its position in shares of Icon by 51.0% during the 1st quarter. Dean Capital Investments Management LLC now owns 2,736 shares of the medical research company’s stock valued at $323,000 after acquiring an additional 924 shares during the last quarter. Finally, First National Bank of Omaha bought a new position in shares of Icon during the 1st quarter valued at approximately $279,000. Hedge funds and other institutional investors own 87.15% of the company’s stock.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Article: Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on Icon (ICLR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com